Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Superficial bladder cancer.

Donald L Lamm1

  • 1Mayo Clinic Scottsdale, 13400 East Shea Boulevard, Scottsdale, AZ 85259, USA. lamm.donald@mayo.edu

Current Treatment Options in Oncology
|August 27, 2002
PubMed
Summary

Superficial bladder cancer treatment varies by risk. Low-risk tumors use chemotherapy, while intermediate and high-risk tumors often require immunotherapy like bacille Calmette-Guérin (BCG).

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Bladder-sparing Therapy for Bacillus Calmette-Guérin-unresponsive Non-muscle-invasive Bladder Cancer: International Bladder Cancer Group Recommendations for Optimal Sequencing and Patient Selection.

European urology·2024
Same author

Reduced Dose Intravesical Bacillus Calmette-Guérin: Why It Might Not Matter.

Bladder cancer (Amsterdam, Netherlands)·2024
Same author

Publisher Correction: Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial.

Nature medicine·2024
Same author

Author Correction: Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial.

Nature medicine·2024
Same author

Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial.

Nature medicine·2024
Same author

A Phase 1 Trial of Durvalumab in Combination with Bacillus Calmette-Guerin (BCG) or External Beam Radiation Therapy in Patients with BCG-unresponsive Non-muscle-Invasive Bladder Cancer: The Hoosier Cancer Research Network GU16-243 ADAPT-BLADDER Study.

European urology·2023

Area of Science:

  • Oncology
  • Urology

Background:

  • Superficial bladder cancer resection has low morbidity but high recurrence risk.
  • Tumor risk stratification is crucial for effective treatment planning.

Purpose of the Study:

  • To outline risk-stratified treatment strategies for superficial bladder cancer.
  • To discuss management options including chemotherapy and immunotherapy.

Main Methods:

  • Categorization of tumors into low-, intermediate-, and high-risk groups based on grade, stage, and recurrence patterns.
  • Review of treatment modalities including intravesical chemotherapy and bacille Calmette-Guérin (BCG) immunotherapy.

Main Results:

  • Low-risk tumors: single chemotherapy instillation (thiotepa, doxorubicin, mitomycin).
  • Intermediate/High-risk tumors: often require immunotherapy, with BCG as a primary option for high-risk cases.
  • BCG side effects can be mitigated by dose reduction; treatment failure may be managed with BCG plus interferon-alfa or cystectomy.

Conclusions:

  • Risk stratification guides superficial bladder cancer treatment selection.
  • Intravesical therapies, including chemotherapy and BCG immunotherapy, are effective but require tailored approaches.
  • Salvage options exist for patients who do not respond to initial BCG therapy.

Related Experiment Videos